HBM Holdings Limited (SEHK: 2142)
Health Care · Biotechnology · CN
HK$15.10
+6.41% today · +19.7% 1Y
HBM Holdings Limited (SEHK: 2142) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.67B and employs 272 people.
Over the last twelve months the share price has gained 19.7%, trading between 9.46 and 17.98.
Tweenvest scores HBM Holdings Limited across four factors: quality 76/100, value 33/100, growth 100/100. Its strongest factor is growth.
2142 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.67B
- Revenue (TTM)
- $157.97M
- P/E
- 17.64
- EPS
- 0.11
- Dividend yield
- —
- Beta (5Y)
- 1.37
- 52-week high
- HK$17.98
- 52-week low
- HK$9.46
- Avg volume (3M)
- —
- Shares outstanding
- 867.61M
- Employees
- 272
- Next earnings
- —
About HBM Holdings Limited
HBM Holdings Limited is a clinical-stage biopharmaceutical enterprise focused on identifying and developing unique antibody-based treatments for a variety of immunological conditions and cancers. The company's pipeline includes several promising assets. In immunology, Batoclimab (HBM9161) is a human monoclonal antibody specifically designed to bind and inhibit the neonatal fragment crystallizable receptor, while Tanfanercept (HBM9036) is under development to address moderate to severe dry eye disease. For oncology, HBM Holdings is advancing various therapies, such as HBM7008, a bispecific antibody targeting tumor-associated antigens, and HBM4003, a human anti-CTLA-4 antibody. Additional cancer candidates in their portfolio include HBM9302 for breast and gastric cancers, HBM7020 for multiple myeloma, and a suite of treatments—HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022—geared towards solid tumors. Furthermore, HBM9022 is being developed to treat SARS-COV-2. Operating globally, HBM Holdings has a presence in Mainland China, the United States, Europe, and other international markets. The company also fosters strategic partnerships for antibody-drug conjugate (ADC) projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was founded in 2016 and is based in Shanghai, People's Republic of China.
- ISIN
- KYG4403H1002
- Founded
- 2016
- Listed since
- Dec 10, 2020
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $261.87 | -1.47% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $440.95 | -0.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.82 | +0.03% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $549.25 | -0.65% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $819.38 | -1.70% |
| argenx SEENXTBR: ARGX | $64.17B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $146.41 | -7.82% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.